CN102134225B - Tricyclic diterpene lactone and preparation method and application thereof - Google Patents
Tricyclic diterpene lactone and preparation method and application thereof Download PDFInfo
- Publication number
- CN102134225B CN102134225B CN2011100096636A CN201110009663A CN102134225B CN 102134225 B CN102134225 B CN 102134225B CN 2011100096636 A CN2011100096636 A CN 2011100096636A CN 201110009663 A CN201110009663 A CN 201110009663A CN 102134225 B CN102134225 B CN 102134225B
- Authority
- CN
- China
- Prior art keywords
- ethyl acetate
- silica gel
- container
- sesquiterpene lactone
- tricyclic sesquiterpene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 7
- -1 diterpene lactone Chemical class 0.000 title abstract description 8
- 229930004069 diterpene Natural products 0.000 title abstract 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 210000000845 cartilage Anatomy 0.000 claims abstract description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000741 silica gel Substances 0.000 claims abstract description 17
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 11
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 8
- 239000013078 crystal Substances 0.000 claims abstract description 6
- 229930009674 sesquiterpene lactone Natural products 0.000 claims description 46
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 claims description 45
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 claims description 41
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 16
- 241000132012 Atractylodes Species 0.000 claims description 15
- 230000004069 differentiation Effects 0.000 claims description 14
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 11
- 238000012856 packing Methods 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 2
- 229940096978 oral tablet Drugs 0.000 claims description 2
- 239000007935 oral tablet Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 229940090044 injection Drugs 0.000 claims 1
- 229940100691 oral capsule Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 238000002156 mixing Methods 0.000 abstract description 5
- 238000010828 elution Methods 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 4
- 238000000605 extraction Methods 0.000 abstract 2
- 239000003208 petroleum Substances 0.000 abstract 2
- 238000002791 soaking Methods 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000006837 decompression Effects 0.000 abstract 1
- 239000003480 eluent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 12
- 101100203200 Danio rerio shha gene Proteins 0.000 description 11
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- 101150088976 shh gene Proteins 0.000 description 11
- 239000003921 oil Substances 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 9
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 5
- 102000027313 Epiphycan Human genes 0.000 description 5
- 108091013881 Epiphycan Proteins 0.000 description 5
- 108010069873 Patched Receptors Proteins 0.000 description 5
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 229950003937 tolonium Drugs 0.000 description 5
- 102100032912 CD44 antigen Human genes 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 4
- 101150106167 SOX9 gene Proteins 0.000 description 4
- 101710198026 Transcription factor SOX-9 Proteins 0.000 description 4
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- ZTVSGQPHMUYCRS-SWLSCSKDSA-N (4as,8as)-3,8a-dimethyl-5-methylidene-4a,6,7,8-tetrahydro-4h-benzo[f][1]benzofuran-2-one Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C=C1C2=C(C)C(=O)O1 ZTVSGQPHMUYCRS-SWLSCSKDSA-N 0.000 description 3
- OQYBLUDOOFOBPO-UHFFFAOYSA-N Asterolide Natural products C1C2C(=C)CCCC2(C)CC2C1=C(C)C(=O)O2 OQYBLUDOOFOBPO-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000000017 Patched Receptors Human genes 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000004081 sesquiterpene lactone group Chemical group 0.000 description 3
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- RBJDJJGMGHKQMI-XETGTQJKSA-N (4ar,8as,9ar)-9a-[(4ar,8as,9ar)-3,8a-dimethyl-5-methylidene-2-oxo-4,4a,6,7,8,9-hexahydrobenzo[f][1]benzofuran-9a-yl]-3,8a-dimethyl-5-methylidene-4,4a,6,7,8,9-hexahydrobenzo[f][1]benzofuran-2-one Chemical compound C([C@@]1(C)C2)CCC(=C)[C@H]1CC1=C(C)C(=O)O[C@@]12[C@@]12C[C@]3(C)CCCC(=C)[C@H]3CC1=C(C)C(=O)O2 RBJDJJGMGHKQMI-XETGTQJKSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ICWHTQRTTHCUHW-IPYPFGDCSA-N 2-[(3s,5r,6r)-6,10-dimethylspiro[4.5]dec-9-en-3-yl]propan-2-ol Chemical compound C[C@@H]1CCC=C(C)[C@]11C[C@@H](C(C)(C)O)CC1 ICWHTQRTTHCUHW-IPYPFGDCSA-N 0.000 description 1
- ICWHTQRTTHCUHW-UHFFFAOYSA-N Agarospirol Natural products CC1CCC=C(C)C11CC(C(C)(C)O)CC1 ICWHTQRTTHCUHW-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 240000004460 Tanacetum coccineum Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RBJDJJGMGHKQMI-UHFFFAOYSA-N biatractylenolide Natural products C1C2(C)CCCC(=C)C2CC2=C(C)C(=O)OC21C12CC3(C)CCCC(=C)C3CC1=C(C)C(=O)O2 RBJDJJGMGHKQMI-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010999 medical injection Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of organic chemistry, and more particularly relates to tricyclic diterpene lactone, the molecular structure of which is shown as formula (I). the compound can be prepared b the following method: (1) taking Rhizoma Atractylodis Macrocephalae decoction pieces, adding a proper amount of ethyl acetate for soaking and extraction for 1-3 times at room temperature, soaking and extraction each time lasts for ten days, an ethyl acetate extracting solution is combined, ethyl acetate is recovered by decompression to obtain an extractum; (2) dissolving the extractum in the ethyl acetate, adding silica gel GF254 with the weight 2-3.5 times of that of the extractum, mixing uniformly, thoroughly volatilizing the ethyl acetate, and obtaining a sample-injected silica gel; filling blank silica gel with the weight 1-3 times of that of the sample-injected silica gel into a chromatographic column and then filling the sample-injected silica gel; conducting continuous gradient elution to an eluent formed by petroleum ether and absolute ethyl alcohol with the flow rate of 0.3 to 10mL/min, collecting crystals separated out from fraction of absolute ethyl alcohol with the volume concentration of 0-0.5 percent in the petroleum ether, and then obtaining tricyclic diterpene lactone. The compound can be used for preparing medicaments for propelling bone mesenchymal stem cells to disperse to cartilage.
Description
Technical field
The invention belongs to organic chemistry filed, be specifically related to Oxygenic heterocyclic compounds, particularly three ring sesquiterpene lactones.
Background technology
Mesenchymal stem cells MSCs (mesenchymal stem cells, MSCs) is one of stem cell of present most study, application potential maximum, is the ideal model of research propagation and differentiation mechanism.But MSCs content is few in the marrow, and a little less than the Long-term Proliferation activity, amplification rate is slow, and is aging to fat gradually, can't satisfy a large amount of clinical demands.Transplanting studies show that in numerous in-vitro transfections and the body, and the MSCs proliferation activity of transplanting is inadequate, and survival volume is less, has seriously limited the applied research of MSCs.And a little less than the MSCs osteogenic activity, ossific process is slower, therefore, how to improve the osteogenic potential of MSCs, makes it efficiently to Chondrocyte Differentiation, will be the key issue in the MSCs differentiation research.Some Chinese medicines and extract thereof, flavonoid compound naringin naringin, hyaluronic acid, poly-l-lysine and antler polypeptide can induced dry-cell to cartilage differentiation.Publication number is that the application for a patent for invention of CN101029303 discloses a kind of induced dry-cell to the material of cartilage differentiation, this material is the mixture of stem cell-Biodegradable material, wherein said Biodegradable material is polylactic acid PLA, polyglycolic acid PGA, polyhydroxybutyrate PGA, poly-acid anhydrides, poly-phosphazo, polyamino acid, false polyamino acid, poe, polycarbonate, the polyester urethane, poly-di-alcohol, polyethylene oxide, poly-para-dioxanone, glue, gelatin, hyaluronic acid, the glycosyl glycan, chitosan, chitin, alginates or acellular matrix, and their minute combinations.These mostly are macromolecular compound, and molecular weight is large, are unfavorable for permeate through cell membranes.
The bighead atractylodes rhizome (rhizoma atractylodis macroephalae) is the dry rhizome of composite family (Compositae) the plant bighead atractylodes rhizome, and is warm in nature, distinguishes the flavor of sweet, bitter; The ground such as main product Zhejiang, Anhui; Has tonifying spleen, beneficial stomach, eliminating dampness, and medium effect.The important chemical composition of the bighead atractylodes rhizome comprises volatile oil, lactone compound, polysaccharide, vitamin A and amino acid etc.Wherein volatile oil is mainly atractylone, hinesol etc. in bighead atractylodes rhizome rhizome approximately 1.4%, is the main position of bighead atractylodes rhizome anti-tumor activity; Soluble polysaccharide is that the bighead atractylodes rhizome is brought into play oxidation resistant main position; Lactone compound is mainly the sesquiterpene lactones compounds, has isolated at present atractylenolide Ⅰ-IV, 8-β-oxyethyl group atractylenolide Ⅰ II, biatractylolide, 8,9-epoxy atractylodes lactone, 4,15 one epoxy hydroxyl atractylodes lactones etc.Wherein, atractylenolide Ⅰ and atractylenolide Ⅰ II have an anti-inflammatory action, be widely used in clinical treatment Aging, struvite osteopathia, so in traditional prescription of many treatments disease relevant with MSC contents level in the marrow, generally use the bighead atractylodes rhizome and other bulk drug to carry out compatibility.Yet, from isolated monomer wherein mesenchymal stem cells MSCs is had no report to the cartilage differentiation effect.
Summary of the invention
For solving the problems of the technologies described above, the invention provides a kind of tricyclic sesquiterpene lactone, this compound has short mesenchymal stem cells MSCs to the cartilage differentiation effect.
For solving the problems of the technologies described above, the technical solution used in the present invention is:
A kind of tricyclic sesquiterpene lactone, its molecular structure is as shown in the formula shown in the I:
The molecular formula of compound shown in the above-mentioned formula I is for being C
15H
20O
3Molecular weight is 248.0, it is colourless acicular crystal under the normal temperature and pressure, called after: 3,8a-dimethyl-5-methylene radical-9a-hydroxyl-perhydronaphthalene [2,3-b]-1,4-dihydrofuran-2-ketone is [English by name: 3,8a-dimethyl-9a-hydroxyl-5-methylene-decahydronaphthalene [2,3-b]-Isosorbide-5-Nitrae-2H-furan-2-one].
Tricyclic sesquiterpene lactone of the present invention can obtain by the method for chemosynthesis, also can separate obtaining from Rhizoma Atractylodis Macrocephalae, and wherein, the step of described chemical synthesis process and processing condition are knowledge well-known to those having ordinary skill in the art.The above-mentioned bighead atractylodes rhizome is that the method that the dry rhizome bighead atractylodes rhizome of feverfew bighead atractylodes rhizome Atractylodes macrocephala Koidz. therefrom separates tricyclic sesquiterpene lactone of the present invention is comprised of following steps:
(1) get bighead atractylodes rhizome medicine materical crude slice, add to soak under an amount of ethyl acetate room temperature and extract 1～3 time, the each immersion extracted ten days, the combined ethyl acetate extracting solution, and the reclaim under reduced pressure ethyl acetate gets medicinal extract;
(2) gained medicinal extract is dissolved in the ethyl acetate, admixes the heavy silica GF254 of 2～3.5 times of medicinal extract, mix, volatilize ethyl acetate, obtain application of sample silica gel; The blank silica gel that the gained application of sample silica gel weight of packing in the chromatography column first is 1～3 times, the application of sample silica gel of then packing into; The elutriant that forms with sherwood oil and dehydrated alcohol carries out the continuous gradient wash-out with the flow velocity of 0.3～10ml/min, collects the volumetric concentration of dehydrated alcohol in sherwood oil and be the crystal of separating out in 0～0.5% the flow point, obtains the tricyclic sesquiterpene lactone.
In the above-mentioned separation method, the flow velocity of described elutriant is relevant with the particle diameter of silica gel, and the large stream of grain is hurried up, otherwise flows a little slower.
In the above-mentioned separation method, described elutriant is by sherwood oil and dehydrated alcohol two phase composites, because wherein the maximum concentration of dehydrated alcohol in sherwood oil only is 0.5%, if therefore use some simple and crude equipments, drips such as bottle, just is difficult to equably dispensing.In order to address the above problem, described continuous gradient elution process can adopt following simple method: with the container A sherwood oil of packing into, another container B dress dehydrated alcohol volumetric concentration is the solution that 0.5% sherwood oil mixes with dehydrated alcohol, then with container B, container A and chromatography column successively setting up and down and connection, make simultaneously at last container B and container A begin lower, and in lower process, the solvent in the container A is stirred.
Tricyclic sesquiterpene lactone of the present invention has short mesenchymal stem cells MSCs to the cartilage differentiation effect, can be used for preparing the medicine for the treatment of cartilage injury, this medicine is comprised of compound and the pharmaceutical excipient shown in the formula I, can be injection, oral tablet, capsule etc.
The below will be by experiment further proof tricyclic sesquiterpene lactone of the present invention have short mesenchymal stem cells MSCs to the cartilage differentiation effect.
1 materials and methods
1.1 reagent and laboratory animal
Cell cultures and reagent: low sugar Da Shi revises Yi Shi substratum (low glucose dulbecco ' s modified eagle ' smedium, L-DMEM), high sugared Da Shi revises Yi Shi substratum (high glucose dulbecco ' s modified eagle ' smedium, H-DMEM), L-DMEM contains D-Glucose 1g/L and L-glutaminate; H-DMEM contains the 4.5g/L D-Glucose and L-glutaminate, Percoll stock solution and ox tire serum (fetal bovine serum, FBS) are Gibcol company product; CO
2Incubator, German Heraeus company product; Inverted phase contrast microscope, Japanese Olympus company product; The CD44 monoclonal mouse antibody is provided by Shenzhen brilliant U.S. company.
Laboratory animal: purebred SD rat, the cleaning level, male and female half and half, at 1～4 month monthly age, body weight 250～300g is provided by Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center.
1.2.MSCs separate, increase and identify
Rat femur, shin bone marrow are gone out with the DMEM that contains 10%FBS, and fully mixing changes centrifuge tube over to, and the centrifugal 10min of 300g removes supernatant, and L-DMEM is resuspended, centrifugal remove supernatant after, add 4ml L-DMEM mixing.The Percoll stock solution mixed by 0.56: 0.44, got 4ml and put into the 10ml centrifuge tube, inhaled bone marrow fluid and was slowly adding from liquid level 2cm place subsides tube wall.The centrifugal 30min of horizontal centrifuge 900g, the collecting monocytic cell layer is used the DMEM washed twice.Then counting cells is adjusted density, by 1 * 10
6/ cm
2Density inoculation, 37 ℃, the CO of 5% saturated humidity
2Incubator is cultivated, and nutrient solution is the L-DMEM that contains 10%FBS, changes nutrient solution behind the 5d, discards not attached cell, and 3～4d changes liquid 1 time, approaches the MSC that merges and digests 2～3min with containing 0.25% pancreatin room temperature, by 1 * 10
4/ cm
2Go down to posterity.After cultivating for 3 generations, take out and do the Flow Cytometry detection.
1.3.MSCs the cartilage differentiation of inducing cultivate
Pass behind the MSCs in 3 generations with 1 * 10
5/ cm
2Cell density is inoculated into 24 well culture plates and 6 orifice plates, and minute negative blank group and tricyclic sesquiterpene lactone are induced group; The tricyclic sesquiterpene lactone component does not add 3,30 μ g/ml tricyclic sesquiterpene lactone of the present invention, and the blank group adds solvent and processes factor, and every 3d changes liquid 1 time, induces 7 days.
1.4 Toluidine blue staining detects cell glycosaminoglycan content
To grow to the cell of logarithmic phase by 1 * 10
5/ cm
2Density is inoculated in the 24 hole versions of cover glass, with above-mentioned each the group induce respectively 7 days after, PBS rinsing cover glass, 1% Toluidine blue staining is after 10 minutes, tri-distilled water embathes, the resinene sealing is observed under the light microscopic.
1.5RT-PCR detect cartilage phenotype related protein gene, SOX9 and Shh signal path
Extract the genome of blank group, tricyclic sesquiterpene lactone group, total RNA carries out according to Trizol test kit specification sheets; RT-PCR adopts Primer Premier5.0 software design primer with reference to the cDNA sequence of Genbank, and is synthetic by Shanghai Ying Jun company.OPN upstream primer: 5-AGTTTGGCAGCTCAGAGGAGAAG-3, downstream primer: 3-GATTGGAGTCAAAACGTCTGCTTG-5; CollagenIX upstream primer: 5-TACCTGGCATGAAGGGCAGTG-3, downstream primer: GTCCTGGAATTCCTGGAGA; Epiphycan upstream primer: 5-GCAAGCTTTGTGTACTGTGA-3, downstream primer: 3-GCTCTGTAGTTGGTGCAG-5; SOX9 upstream primer: 5-CGGCGGAGGAAGTCGGTGAAGA-3, downstream primer: 3-CGTTGGGCGGCAGGTATTGGTC-5; Patched upstream primer: 5-CCTCCTTTACGGTGGACAAA-3, downstream primer: 3-CAGTGGCGTTCTTGACGG-5; Gli-1 upstream primer: 5-AAGCATCAGAACCGCACCCACTC-3, downstream primer: 3-CCACCCGTGTTGCCCGTCATCTC-5; GAPDH upstream primer: 5-TAAAGGGCATCCTGGGCTACACT-3, downstream primer: 5-TTACTCCTTGGAGGCCATGTAGG-3.Reaction conditions is: 93 ℃ of 2min, 93 ℃ of 45seconds then, 63 ℃ of 30secends, totally 30 circulations.Reaction is got the PCR reaction solution and is carried out agarose gel electrophoresis after finishing.The RT-PCR product carries out absorbancy scanning through 1.5% agarose gel electrophoresis with image analyzer.
2 results
2.1 the Flow Cytometry result utilizes Flow cytometry cell-surface antigens CD44 cell sign, found that the CD44 positive cell reaches 98.14% (seeing Fig. 1), shows that cultivating resulting cell is MSC.
2.2 Toluidine blue staining found that, tricyclic sesquiterpene lactone rising cell glycosaminoglycan content (seeing Fig. 2) shows that the tricyclic sesquiterpene lactone promotes the cartilage differentiation of inducing of MSCs.
2.2 the tricyclic sesquiterpene lactone promotes the expression of cartilage phenotype genes involved
0,3,30 μ g/ml tricyclic sesquiterpene lactones acted on respectively MSCs 3 days, 6 days, and collecting cell extracts cell RNA, and RT-PCR detects CollagenIX, the variation of Epiphycan and OPN.The result of RT-PCR shows, the expression of the promotion of tricyclic sesquiterpene lactone cartilage phenotype genes involved CollagenIX (seeing Fig. 3), Epiphycan (seeing Fig. 4), OPN (seeing Fig. 5).Fig. 3 ordinate zou represents the ratio of CollagenIX and confidential reference items GAPDH; *, compare with control group in P＜0.05.Fig. 4 ordinate zou represents the ratio of Epiphycan and confidential reference items GAPDH; *, compare with control group in P＜0.05.Fig. 5 ordinate zou represents the ratio of OPN and confidential reference items GAPDH; *, compare with control group in P＜0.05.
2.3 the tricyclic sesquiterpene lactone promotes the expression of cartilage phenotype associated transcription factor Sox9 gene
0,3,30 μ g/ml tricyclic sesquiterpene lactones acted on respectively MSCs 3 days, 6 days, and collecting cell extracts cell RNA, and RT-PCR detects the variation of Sox9.The tricyclic sesquiterpene lactone that shows of RT-PCR promotes the expression (seeing Fig. 6) of cartilage phenotype associated transcription factor Sox9 gene.Fig. 6 ordinate zou represents the ratio of Sox9 and confidential reference items GAPDH.*, compare with control group in P＜0.05.
2.4 the tricyclic sesquiterpene lactone activates the Shh signal path
0,3,30 μ g/ml tricyclic sesquiterpene lactones acted on respectively MSCs 3 days, 6 days, and collecting cell extracts cell RNA, and RT-PCR detects the variation of patched gene and Gli-1.The result of RT-PCR shows, the expression (seeing Fig. 7 and 8) of tricyclic sesquiterpene lactone promotion Shh signal path acceptor patched gene and Shh signal path target gene Gli-1.Fig. 7 ordinate zou represents the ratio of patched and confidential reference items GAPDH.*, compare with control group in P＜0.05.Fig. 8 ordinate zou represents the ratio of Gli-1 and confidential reference items GAPDH.*, compare with control group in P＜0.05.
2.5 the tricyclic sesquiterpene lactone promotes the expression of cartilage phenotype gene to depend on the Shh signal path
Tricyclic sesquiterpene lactone, Cyclopamine, tricyclic sesquiterpene lactone and Cyclopamine acted on respectively MSCs 6 days, and collecting cell extracts cell RNA, and RT-PCR detects the variation (seeing Fig. 9) of Sox9 and Gli-1.The result of RT-PCR shows, the expression (seeing Figure 10) of Shh signal path blocker Cyclopamine inhibition tricyclic sesquiterpene lactone promotion cartilage phenotype gene.Fig. 9 ordinate zou represents the ratio of Sox9 and confidential reference items GAPDH; #, compare with control group in P＜0.05; * compare with tricyclic sesquiterpene lactone group in P＜0.05.Figure 10 ordinate zou represents the ratio of Gli-1 and confidential reference items GAPDH.#, compare with control group in P＜0.05; * compare with tricyclic sesquiterpene lactone group in P＜0.05.Prompting tricyclic sesquiterpene lactone promotes the expression of cartilage phenotype gene to depend on the Shh signal path.
In sum, the present invention acts on the different time of MSCs with the tricyclic sesquiterpene lactone of different concns, use method that Toluidine blue staining detects cell glycosaminoglycan content and RT-PCR and detect the expression of cartilage differentiation phenotype genes, determined that the tricyclic sesquiterpene lactone induces MSCs to the effect of cartilage differentiation.
Description of drawings
Fig. 1 Flow cytometry is cultivated 3 generation MSCs surface antigen CD44 marking patterns.
Fig. 2 tricyclic sesquiterpene lactone acts on respectively 6 days Toluidine blue staining figure of MSCs.
Fig. 3 tricyclic sesquiterpene lactone promotes the expression of cartilage phenotype genes involved CollagenIX.
Fig. 4 tricyclic sesquiterpene lactone promotes the expression of cartilage phenotype genes involved Epiphycan.
Fig. 5 tricyclic sesquiterpene lactone promotes the expression of cartilage phenotype genes involved OPN.
Fig. 6 tricyclic sesquiterpene lactone promotes the expression of the relevant associated transcription factor Sox9 of cartilage phenotype.
Fig. 7 tricyclic sesquiterpene lactone promotes the expression of Shh signal path acceptor patched.
Fig. 8 tricyclic sesquiterpene lactone promotes the expression of Shh signal path target gene Gli-1.
Fig. 9 Shh signal path blocker Cyclopamine suppresses the expression that the tricyclic sesquiterpene lactone promotes cartilage phenotype associated transcription factor Sox9.
Figure 10 Shh signal path blocker Cyclopamine suppresses the expression that the tricyclic sesquiterpene lactone promotes Gli-1.
Embodiment
1, the preparation of compound
(1) get 1kg bighead atractylodes rhizome medicine materical crude slice and add an amount of ethyl acetate, be limited to soak fully, at room temperature soak 2 times, soaked ten days at every turn, the combined ethyl acetate extracting solution, the reclaim under reduced pressure ethyl acetate gets medicinal extract 24g.
(2) medicinal extract is dissolved in the 48mL ethyl acetate, admixes 200～300 purpose silica GF254s of 76g, mix, volatilize ethyl acetate, obtain application of sample silica gel;
(3) in chromatography column, the blank silica gel of the 76g that packs into first reinstalls application of sample silica gel;
(4) concentration of packing in container A is 100% sherwood oil, and the dehydrated alcohol volumetric concentration of packing in the container B is the solution that 0.5% dehydrated alcohol mixes with sherwood oil, and container B is suspended from the top of container A, is communicated with, and outlet is joined with the top of chromatography column under the container A; Then, solvent in container B and the container A is dripped downwards simultaneously, wherein the mixing solutions in the container B is added dropwise in the sherwood oil of container A with 0.3-10ml/min speed, and stir, solvent in the container A injects the chromatography column upper end with 0.3-10ml/min speed and carries out wash-out, collect the volumetric concentration of dehydrated alcohol in sherwood oil and be the crystal of separating out in 0～0.5% the flow point, obtain tricyclic sesquiterpene lactone 4.8g, yield is 0.06%.
2, the evaluation of compound
Identify: molecular formula C
15H
22O
3, be colourless acicular crystal under the normal temperature and pressure; EI-MS (M)
+: 248.0; IR v
Max KBr(cm
-1): 2933,1759,1674,1649,889.UVλ
max?
MeOH：242nm；
1H-NMR,
13C-NMR, HMBC data see Table 1.
Table 1
1H-NMR (400MHz) and
13C-NMR (100MHz)
Prescription:
With the compound that example 1 obtains, adopt the preparation method of medical injection to make injection liquid.This compound 500mg is dissolved in 1,2 propylene glycol 20ml and tween-80 2ml, injects water to again 250ml.Pour into after mixing in the bottle, sealing, the injection liquid of one of 2mg/1ml is made in sterilization.This product is used for intravenous injection (iv.), is grown up 2mg/ days, is equivalent to 1; Children's's usual amounts: by body weight 0.05mg/kg/ days.
Prescription:
The compound that example 1 is obtained adopts the preparation method of capsule for medicine to make capsule.With this compound 25000mg, add calcium carbonate 4500mg, add starch 500mg.Mix granulation, can becomes that every intragranular is tolerant to be the capsule of 30mg, and every capsules contains this product 25mg.
Instructions of taking: oral, adult's usual amounts, every day 2 times, each 1-2 grain; Children's's usual amounts, by 0.5mg/kg of body weight, per six hours once.4 weeks were a course for the treatment of, and after two courses for the treatment of, dose cuts down according to the circumstance.
Embodiment 4
Prescription:
The compound that example 1 is obtained adopts the preparation method of medicinal tablets to make tablet, with this compound 40000mg, adds calcium carbonate 9000mg, adds starch 1000mg.Mix, cross 90 mesh sieves, compressing tablet.Make sheet and heavily be the tablet of 50mg, every contains this product 40mg.
Instructions of taking: oral, adult's usual amounts, every day 2 times, each 1-2 sheet; Children's's usual amounts, by 0.5mg/kg of body weight, per six hours once.4 weeks were a course for the treatment of, and after two courses for the treatment of, dose cuts down according to the circumstance.
Claims (5)
1. the tricyclic sesquiterpene lactone is in the application of the short mesenchymal stem cells MSCs of preparation in the medicine of cartilage differentiation, and the molecular structure of wherein said tricyclic sesquiterpene lactone is as shown in the formula shown in the I:
2. application according to claim 1 is characterized in that, described medicine is comprised of tricyclic sesquiterpene lactone claimed in claim 1 and pharmaceutical excipient.
3. application according to claim 2 is characterized in that, described medicine is injection, oral tablet or capsule.
4. application according to claim 1 is characterized in that, described tricyclic sesquiterpene lactone is prepared by following methods:
(1) get bighead atractylodes rhizome medicine materical crude slice, add to soak under an amount of ethyl acetate room temperature and extract 1～3 time, the each immersion extracted ten days, the combined ethyl acetate extracting solution, and the reclaim under reduced pressure ethyl acetate gets medicinal extract;
(2) gained medicinal extract is dissolved in the ethyl acetate, admixes the heavy silica GF254 of 2～3.5 times of medicinal extract, mix, volatilize ethyl acetate, obtain application of sample silica gel; The blank silica gel that the gained application of sample silica gel weight of packing in the chromatography column first is 1～3 times, the application of sample silica gel of then packing into; The elutriant that forms with sherwood oil and dehydrated alcohol carries out the continuous gradient wash-out with the flow velocity of 0.3～10ml/min, collects the volumetric concentration of dehydrated alcohol in sherwood oil and be the crystal of separating out in 0～0.5% the flow point, obtains the tricyclic sesquiterpene lactone.
5. application according to claim 4, it is characterized in that, the method of described continuous gradient wash-out is: with the container A sherwood oil of packing into, another container B dress dehydrated alcohol volumetric concentration is the solution that 0.5% sherwood oil mixes with dehydrated alcohol, then with container B, container A and chromatography column successively setting up and down and connection, make simultaneously at last container B and container A begin lower, and in lower process, the solvent in the container A is stirred.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100096636A CN102134225B (en) | 2011-01-17 | 2011-01-17 | Tricyclic diterpene lactone and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100096636A CN102134225B (en) | 2011-01-17 | 2011-01-17 | Tricyclic diterpene lactone and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102134225A CN102134225A (en) | 2011-07-27 |
| CN102134225B true CN102134225B (en) | 2013-04-03 |
Family
ID=44294176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100096636A Expired - Fee Related CN102134225B (en) | 2011-01-17 | 2011-01-17 | Tricyclic diterpene lactone and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102134225B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106190965A (en) * | 2016-07-19 | 2016-12-07 | 袁肇斌 | A kind of mesenchymal stem cells MSCs In vitro culture liquid and cultivation amplification method |
| CN107574147B (en) * | 2017-10-20 | 2018-11-23 | 湖南源品细胞生物科技有限公司 | A kind of mescenchymal stem cell Proliferation, Differentiation culture solution |
| CN107674053B (en) * | 2017-10-23 | 2019-08-20 | 北京恒生佳合细胞科技有限公司 | A kind of atractylodes lactone V, preparation method and the application of aspect is frozen in CIK cell |
| CN109022353B (en) * | 2018-08-26 | 2021-11-02 | 山东兴瑞生物科技有限公司 | Bone morphogenetic protein 2 activator and application thereof in promoting osteogenic differentiation of mesenchymal stem cells |
| CN111233629B (en) * | 2020-03-11 | 2022-12-09 | 河南中医药大学 | Method for preparing compound BZ-92 from traditional Chinese medicine bighead atractylodes rhizome |
| CN112939909B (en) * | 2021-01-15 | 2022-06-21 | 宁波大学 | Nano-docetaxel condensation compound and preparation method and application thereof |
-
2011
- 2011-01-17 CN CN2011100096636A patent/CN102134225B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| Katsuya endo et al.Antiinflammatory principles of atractylodes rhizomes.《Chemical & Pharmaceutical Bulletin》.1979,第27卷(第12期),2954-2958. |
| Katsuya endo et al.Antiinflammatory principles of atractylodes rhizomes.《Chemical & * |
| Pharmaceutical Bulletin》.1979,第27卷(第12期),2954-2958. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102134225A (en) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102134225B (en) | Tricyclic diterpene lactone and preparation method and application thereof | |
| CN111635380B (en) | Sesquiterpene in mugwort, pharmaceutical composition thereof, preparation method and application thereof | |
| CN105111269A (en) | Novel limonin compound as well as preparation method and medical application thereof | |
| CN101824014B (en) | Compound separated from chloranthus japonicus and having antitumor activity and application thereof | |
| CN105963343B (en) | A kind of compound Codonopsis pilosula total saposins immune polysaccharide nano emulsion composition and preparation method thereof | |
| CN104817609B (en) | Arasaponin compound with resisting liver cancer activity and preparation method and application | |
| CN109674866A (en) | A kind of anti-human primary gastrointestinal cancers pharmaceutical composition, preparation method and applications | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN1977885B (en) | Antihepatitis medicinal composition | |
| CN102417509B (en) | Application of three compounds extracted from starfish to promotion of bone fracture healing, and preparation method for three compounds | |
| CN104906083B (en) | The new application of iridoid | |
| CN108452240B (en) | Anti-tumor traditional Chinese medicine composition and application thereof | |
| CN101822657B (en) | Pachysandra terminalis alkaloid compound for resisting tumor metastasis | |
| CN101318946B (en) | Dimeric ainsliaea terpene A, preparation and application thereof | |
| CN105481878A (en) | Novel limonin compound and preparation method and medical application thereof | |
| CN105384721A (en) | Novel biphenyl cyclooctene lignin compound, and preparation method and application thereof | |
| CN111150752A (en) | Application of abrus herb extract in preparing anticancer medicine | |
| CN105418727A (en) | Novel ursanes diterpenoid compound and preparation method and medical application thereof | |
| CN105481932A (en) | Triterpenoid saponins compound, and preparation method and uses thereof | |
| CN104546988A (en) | Preparation method of trichosanthes kirilowii Maxim polysaccharide immunopotentiator | |
| CN104693263B (en) | A kind of arasaponin compound with anti-tumor activity and preparation method and application | |
| CN114621094B (en) | Compound with islet protection function and preparation method and application thereof | |
| CN114748490B (en) | Pharmaceutical composition for treating premature ovarian failure, application and preparation method thereof | |
| CN105254492A (en) | Novel triterpenoid for liver protection and preparation method thereof | |
| CN101318966B (en) | Dimerized sesquiterpenoids, preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130403 |